Phase 1 Cutaneous Melanoma trials recruiting now
All Cutaneous Melanoma trials, every phase
12
Phase 1 recruiting
Other phases for Cutaneous Melanoma
Phase 1 Cutaneous Melanoma trials
- A Beta-only IL-2 ImmunoTherapY Study
- A First-in-Human Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of KUP-101A in Patients With Selected Advanced Solid Tumors
- A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
- A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
- A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
- A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
- ACTengine® IMA203 Combined With mRNA-4203
- Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma
- Phase 1 Study of PF-08046033 in Advanced Solid Tumors
- Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours
- Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
- Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
Common questions
What does Phase 1 mean?
Is this list complete?
No. For the full record, search ClinicalTrials.gov.